- Home
- ATRC
ATRC
AtriCure Inc.
as 07-26-2024 4:00pm EST
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as AtriCure Inc. ATRC prepares to release earnings report on 30 Jul 2024.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MASON |
| Market Cap: | 1.0B | IPO Year: | 2005 |
| Target Price: | $45.00 | AVG Volume (30 days): | 982.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.94 - $57.77 | Next Earning Date: | 07-30-2024 |
| Revenue: | $414,602,000 | Revenue Growth: | 18.70% |
| Revenue Growth (this year): | 18.03% | Revenue Growth (next year): | 13.77% |
Stock Insider Trading Activity of AtriCure Inc. (ATRC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Privitera Salvatore | ATRC | Chief Technical Officer | May 30 '24 | Buy | $22.25 | 5,000 | $111,250.00 | 103,290 | SEC Form 4 |
| Noznesky Justin J | ATRC | Chief Mktg & Strategy Officer | May 1 '24 | Sell | $24.09 | 1,500 | $36,135.00 | 71,284 | SEC Form 4 |
| Noznesky Justin J | ATRC | Chief Mktg & Strategy Officer | Apr 1 '24 | Sell | $30.39 | 1,500 | $45,585.00 | 72,784 | SEC Form 4 |
| Dahlquist Karl S. | ATRC | Chief Legal Officer | Mar 18 '24 | Sell | $32.16 | 1,885 | $60,621.60 | 50,954 | SEC Form 4 |
| Noznesky Justin J | ATRC | Chief Mktg & Strategy Officer | Mar 12 '24 | Sell | $36.72 | 1,500 | $55,080.00 | 74,284 | SEC Form 4 |
| Dahlquist Karl S. | ATRC | Chief Legal Officer | Mar 5 '24 | Sell | $37.36 | 8,231 | $307,510.16 | 52,839 | SEC Form 4 |
Latest AtriCure Inc. News
ATRC Breaking Stock News: Dive into ATRC Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
MT Newswires
3 days ago
AtriCure Receives Regulatory Nod for AtriClip Heart-Surgery Device in China
Business Wire
4 days ago
AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China
Business Wire
18 days ago
AtriCure to Announce Second Quarter 2024 Financial Results
Simply Wall St.
19 days ago
AtriCure And Two Other Undervalued Small Caps With Insider Actions In The United States
Simply Wall St.
24 days ago
AtriCure Leads Three Undervalued Small Caps With Insider Actions In United States
Simply Wall St.
a month ago
Exploring Three Undervalued Small Caps With Insider Action In The Region
Simply Wall St.
a month ago
Exploring Undervalued Small Caps With Insider Buying In The United States June 2024
Compare ATRC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATRC AtriCure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.